Optimizing targeted therapy for metastatic melanoma: a combination of encorafenib and trametinib beyond standard protocols. Dermatology Reports, [S. l.], 2025. DOI: 10.4081/dr.2025.10036. Disponível em: https://journals.pagepress.org/dr/article/view/10036. Acesso em: 18 jun. 2025.